These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 11439963)

  • 1. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
    Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
    N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
    Wilcox WR; Banikazemi M; Guffon N; Waldek S; Lee P; Linthorst GE; Desnick RJ; Germain DP;
    Am J Hum Genet; 2004 Jul; 75(1):65-74. PubMed ID: 15154115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.
    Thurberg BL; Randolph Byers H; Granter SR; Phelps RG; Gordon RE; O'Callaghan M
    J Invest Dermatol; 2004 Apr; 122(4):900-8. PubMed ID: 15102080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
    Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
    Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
    Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease.
    Wraith JE; Tylki-Szymanska A; Guffon N; Lien YH; Tsimaratos M; Vellodi A; Germain DP
    J Pediatr; 2008 Apr; 152(4):563-70, 570.e1. PubMed ID: 18346516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
    Germain DP; Hughes DA; Nicholls K; Bichet DG; Giugliani R; Wilcox WR; Feliciani C; Shankar SP; Ezgu F; Amartino H; Bratkovic D; Feldt-Rasmussen U; Nedd K; Sharaf El Din U; Lourenco CM; Banikazemi M; Charrow J; Dasouki M; Finegold D; Giraldo P; Goker-Alpan O; Longo N; Scott CR; Torra R; Tuffaha A; Jovanovic A; Waldek S; Packman S; Ludington E; Viereck C; Kirk J; Yu J; Benjamin ER; Johnson F; Lockhart DJ; Skuban N; Castelli J; Barth J; Barlow C; Schiffmann R
    N Engl J Med; 2016 Aug; 375(6):545-55. PubMed ID: 27509102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.
    Eng CM; Banikazemi M; Gordon RE; Goldman M; Phelps R; Kim L; Gass A; Winston J; Dikman S; Fallon JT; Brodie S; Stacy CB; Mehta D; Parsons R; Norton K; O'Callaghan M; Desnick RJ
    Am J Hum Genet; 2001 Mar; 68(3):711-22. PubMed ID: 11179018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy in patients with Fabry's disease.
    Tsuboi K
    J Int Med Res; 2007; 35(4):574-81. PubMed ID: 17697536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
    Mignani R; Cagnoli L
    J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease.
    Masugata H; Senda S; Goda F; Yamagami A; Okuyama H; Kohno T; Hosomi N; Yukiiri K; Noma T; Murao K; Kohno M; Itoh S
    Tohoku J Exp Med; 2009 Mar; 217(3):169-74. PubMed ID: 19282651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.
    Eto Y; Ohashi T; Utsunomiya Y; Fujiwara M; Mizuno A; Inui K; Sakai N; Kitagawa T; Suzuki Y; Mochizuki S; Kawakami M; Hosoya T; Owada M; Sakuraba H; Saito H
    J Inherit Metab Dis; 2005; 28(4):575-83. PubMed ID: 15902561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravenous enzyme substitution therapy in children with Fabry's disease].
    Tøndel C; Laegreid LM; Hirth A; Houge G; Månsson JE; Søvik O
    Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3388-90. PubMed ID: 14713976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.